| Name | Title | Contact Details |
|---|
We work to improve the well-being of individuals and families by delivering quality, comprehensive physical and behavioral healthcare services. We coordinate services for the needs of all who seek care, regardless of socioeconomic status. We partner for creative solutions to meet the diverse needs of individuals, families and communities.
In 2015, five seminal randomized controlled trials were published in the neurovascular space demonstrating endovascular thrombectomy to be the new gold standard for treating large vessel occlusion strokes. During that same year, advancements in artificial intelligence and deep learning made it possible to analyze medical imaging rapidly and accurately. However, despite having proven effective interventions for stroke, most stroke patients were getting treatment late or not at all. At Stanford University, Dr. Chris Mansi (neurosurgeon) and Dr. David Golan (machine learning researcher) identified this problem and together they sought to change it.
At Spineology, we are dedicated to transforming spine surgery by providing innovative, anatomy-conserving technologies for surgeons and their patients. Our proprietary mesh technology is used in the OptiMesh and Duo implants, which expand in three dimensions to create large footprints and allow placement of anatomy-conforming interbody fusion devices through very small incisions. This technology preserves spinal anatomy, increases procedural efficiency, and accelerates patient recovery.
CryoLife`s mission is to partner with clinicians to restore health by delivering innovative technologies. CryoLife is one of the world`s leading medical device companies, providing preserved human tissues for cardiac and vascular surgeries, mechanical heart valves for aortic or mitral valve replacement, surgical adhesives and sealants, vascular grafts, and state-of-the-art technology and surgical training in adult and pediatric cardiovascular surgery. CryoLife is a pioneer and leader in processing, preserving and distributing human tissues, for use in cardiac and vascular surgeries. Founded in 1984, CryoLife was the first biomedical company to specialize in low temperature preservation of human heart valves used for complex cardiac reconstruction, primarily in children born with heart defects. Since the company`s inception, it is estimated that Cryolife has received tissues from over 145,000 donors and CryoLife products and tissues have been implanted in over 1 million patients worldwide. CryoLife is headquartered in Kennesaw, Georgia, with offices in Austin, Texas, Guildford, Surrey, UK, and Hechingen, Germany, as well as sales and marketing centers in Singapore, and representation in over 85 countries worldwide. The firm`s 1000+ employees hail from 11 countries and speak 17 languages. CryoLife`s staff includes numerous full-time physicians and Ph.D.s, with disciplines in chemical engineering, biomedical engineering, biochemistry, protein chemistry and organic chemistry. CryoLife is a public company and is traded on the New York Stock Exchange under the symbol CRY.
BIOCARDIA is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.